NASDAQ:FPRX Five Prime Therapeutics (FPRX) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$38.00▼$38.0050-Day Range$37.65▼$38.0052-Week Range$2.61▼$38.90VolumeN/AAverage Volume1.98 million shsMarket Capitalization$1.77 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Five Prime Therapeutics alerts: Email Address Ad Porter & CompanyWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.Click here to learn how you can benefit from its widespread distribution. About Five Prime Therapeutics Stock (NASDAQ:FPRX)Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.Read More Ad Porter & CompanyWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.Click here to learn how you can benefit from its widespread distribution. FPRX Stock News HeadlinesAugust 9, 2024 | yahoo.comPlay Five Card Draw Online for Free | Yahoo! GamesMarch 28, 2024 | seekingalpha.comCMMB Chemomab Therapeutics Ltd.September 15, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. October 15, 2023 | nbcnews.com33+ best October Prime Day deals you can still shop right nowOctober 11, 2023 | benzinga.comNK Cell Therapy Pipeline, Clinical Trials Studies, Emerging Drugs, and FDA Approvals 2023 (Updated)October 3, 2023 | nypost.comThe Giants’ prime time TV demons are haunting them nowAugust 3, 2023 | forbes.comWhat Is The Prime Rate Today?July 23, 2023 | usatoday.comWant $5? Amazon Prime members can get $5 off a $50 Amazon eGift Card right nowSeptember 15, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. July 5, 2023 | forbes.comPrime Therapeutics Hires New CEO To Lead Pharmacy Benefit Combination With MagellanRxJuly 2, 2023 | usatoday.comGet ready for Amazon Prime Day 2023 with Prime membership discounts available nowMarch 30, 2023 | benzinga.comPrime Therapeutics announces Mostafa Kamal as presidentMarch 19, 2023 | finance.yahoo.comPrime Therapeutics and Magellan Rx to present seven managed care pharmacy research studies at AMCP conferenceMarch 1, 2023 | marketwatch.com2023-2029 Cystic Fibrosis (CF) Therapeutics Market Size and Porters Five Forces Analysis | Survey Report by Absolute ReportsOctober 27, 2022 | marketwatch.comMicrobiome Therapeutics Market 2022 Expected to Reach Significant Rate by 2025September 22, 2021 | feeds.bizjournals.comOral Covid vaccine developer nails down Peninsula spaceAugust 3, 2021 | nasdaq.comFive Prime Therapeutics, Inc. Common Stock (FPRX)See More Headlines Receive FPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Five Prime Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2020Today9/15/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:FPRX CUSIPN/A CIK1175505 Webwww.fiveprime.com Phone415-365-5600FaxN/AEmployees87Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-137,200,000.00 Net Margins-554.71% Pretax MarginN/A Return on Equity-75.84% Return on Assets-49.08% Debt Debt-to-Equity RatioN/A Current Ratio5.35 Quick Ratio5.35 Sales & Book Value Annual Sales$14.87 million Price / Sales119.01 Cash FlowN/A Price / Cash FlowN/A Book Value$4.13 per share Price / Book9.20Miscellaneous Outstanding Shares46,572,000Free FloatN/AMarket Cap$1.77 billion OptionableOptionable Beta4.40 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Helen Louise Collins (Age 58)Exec. VP & Chief Medical Officer Comp: $637.25kMr. Francis W. Sarena (Age 50)Chief Strategy Officer & Sec. Comp: $646.49kMr. Thomas Civik (Age 52)Pres, CEO & Director Mr. David V. Smith M.B.A. (Age 61)Exec. VP & CFO Mr. David White (Age 57)Principal Accounting Officer Mr. Martin ForrestVP of Investor Relations & Corp. CommunicationsDr. Nallakkan S. ArvindanSr. VP of Strategic Technology OperationsMore ExecutivesKey CompetitorsAmphastar PharmaceuticalsNASDAQ:AMPHCalliditas Therapeutics AB (publ)NASDAQ:CALTPhibro Animal HealthNASDAQ:PAHCRadius RecyclingNASDAQ:RDUSEsperion TherapeuticsNASDAQ:ESPRView All Competitors FPRX Stock Analysis - Frequently Asked Questions How were Five Prime Therapeutics' earnings last quarter? Five Prime Therapeutics, Inc. (NASDAQ:FPRX) announced its quarterly earnings results on Friday, November, 6th. The biotechnology company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by $0.14. The biotechnology company earned $2.05 million during the quarter, compared to the consensus estimate of $3.50 million. Five Prime Therapeutics had a negative net margin of 554.71% and a negative trailing twelve-month return on equity of 75.84%. Read the conference call transcript. What other stocks do shareholders of Five Prime Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Five Prime Therapeutics investors own include Pfizer (PFE), Nektar Therapeutics (NKTR), OPKO Health (OPK), TG Therapeutics (TGTX), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE) and Sangamo Therapeutics (SGMO). This page (NASDAQ:FPRX) was last updated on 9/15/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredKamala Harris and The Woke Progressive NightmareNew research from Jim Rickards - former advisor to the CIA - reveals shocking predictions about an “Election M...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredInvest before this deal closes on 9/18This company can create aviation fuels from waste, they qualify to help airlines meet net-zero carbon pledges ...Deal Maker | SponsoredFortune: Nexus Technology has “ignited a gold rush”Business Insider estimates it could grow 8,966% in the near future... And Goldman Sachs says it could grow ...Behind the Markets | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Five Prime Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Five Prime Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.